dc.contributor.author	Mirzaeinia, Somayyeh
dc.contributor.author	Zeinali, Sedighe
dc.contributor.author	Budisa, Nediljko
dc.contributor.author	Karbalaei-Heidari, Hamid Reza
dc.date.accessioned	2022-04-13T14:15:45Z
dc.date.available	2022-04-13T14:15:45Z
dc.date.issued	2022-03-24
dc.date.updated	2022-04-09T14:31:28Z
dc.description.abstract	Biological metal-organic frameworks (BioMOFs) are hybrid compounds in which metal nodes are linked to biocompatible organic ligands and have potential for medical application. Herein, we developed a novel BioMOF modified with an anti-VEGFR1 scFv antibody (D16F7 scFv). Our BioMOF is co-loaded with a combination of an anticancer compound and a lipid-lowering drug to simultaneously suppress the proliferation, growth rate and metastases of cancer cells in cell culture model system. In particular, Prodigiosin (PG) and Simvastatin (SIM) were co-loaded into the newly synthesized Ca-Gly BioMOF nanoparticles coated with maltose and functionalized with a recombinant maltose binding protein-scFv fragment of anti-VEGFR1 (Ca-Gly-Maltose-D16F7). The nanoformulation, termed PG + SIM-NP-D16F7, has been shown to have strong active targeting behavior towards VEGFR1-overexpresing cancer cells. Moreover, the co-delivery of PG and SIM not only effectively inhibits the proliferation of cancer cells, but also prevents their invasion and metastasis. The PG + SIM-NP-D16F7 nanocarrier exhibited stronger cytotoxic and anti-metastatic effects compared to mono-treatment of free drugs and drug-loaded nanoparticles. Smart co-delivery of PG and SIM on BioMOF nanoparticles had synergistic effects on growth inhibition and prevented cancer cell metastasis. The present nanoplatform can be introduced as a promising tool for chemotherapy compared with mono-treatment and/or non-targeted formulations.	en
dc.description.sponsorship	DFG, 414044773, Open Access Publizieren 2021 - 2022 / Technische Universität Berlin	en
dc.identifier.eissn	2296-4185
dc.identifier.uri	https://depositonce.tu-berlin.de/handle/11303/16727
dc.identifier.uri	http://dx.doi.org/10.14279/depositonce-15505
dc.language.iso	en	en
dc.rights.uri	https://creativecommons.org/licenses/by/4.0/	en
dc.subject.ddc	570 Biowissenschaften; Biologie	de
dc.subject.other	chemotherapy	en
dc.subject.other	BioMOF	en
dc.subject.other	prodigiosin	en
dc.subject.other	simvastatin	en
dc.subject.other	co-delivery	en
dc.title	Targeted Codelivery of Prodigiosin and Simvastatin Using Smart BioMOF: Functionalization by Recombinant Anti-VEGFR1 scFv	en
dc.type	Article	en
dc.type.version	publishedVersion	en
dcterms.bibliographicCitation.articlenumber	866275	en
dcterms.bibliographicCitation.doi	10.3389/fbioe.2022.866275	en
dcterms.bibliographicCitation.journaltitle	Frontiers in Bioengineering and Biotechnology	en
dcterms.bibliographicCitation.originalpublishername	Frontiers	en
dcterms.bibliographicCitation.originalpublisherplace	Lausanne	en
dcterms.bibliographicCitation.volume	10	en
tub.accessrights.dnb	free	en
tub.affiliation	Fak. 2 Mathematik und Naturwissenschaften::Inst. Chemie::FG Biokatalyse	de
tub.affiliation.faculty	Fak. 2 Mathematik und Naturwissenschaften	de
tub.affiliation.group	FG Biokatalyse	de
tub.affiliation.institute	Inst. Chemie	de
tub.publisher.universityorinstitution	Technische Universität Berlin	en

Targeted Codelivery of Prodigiosin and Simvastatin Using Smart BioMOF: Functionalization by Recombinant Anti-VEGFR1 scFv

Files

Original bundle

License bundle

Collections